Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00309712 · ClinicalTrials.gov registry record · NA
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study
A NA study, sponsored by Intermountain Health Care.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT00309712 is a NA study that has completed, run by Intermountain Health Care. The registered enrollment target is 300 participants.
The verdict
NCT00309712, a NA study, has completed, sponsored by Intermountain Health Care.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of \<200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
Interventions
- DRUG fenofibrate 160 mg and placebo
- DRUG simvastatin 20 mg and placebo
- DRUG fenofibrate 160 mg and simvastatin 20 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-08 |
| Est. Completion | 2006-09 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00309712
The ClinicalTrials.gov registry entry for NCT00309712 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Intermountain Health Care, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which fenofibrate 160 mg and placebo is the first listed.
NCT00309712 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00309712 about?
NCT00309712 is a clinical study titled "Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study". The primary study hypothesis of this study is to determine whether there is a greater percentage of patients achieving a triglyceride level of \<200 mg/dL with the combination of simvastatin 20 mg and fenofibrate 160mg than with either simvastatin 20 mg monotherapy or fenofibrate 160mg monotherapy.
What is the current status of trial NCT00309712?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2002-08. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00309712?
The interventions under investigation include: fenofibrate 160 mg and placebo (DRUG), simvastatin 20 mg and placebo (DRUG), fenofibrate 160 mg and simvastatin 20 mg (DRUG).
Who is sponsoring clinical trial NCT00309712?
This trial is sponsored by Intermountain Health Care, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.